Page 115 - 《中国药房》2022年21期

[ 6 ] BACHANOVA V，TAM C S，BORCHMANN P，et al. Im‐ B-cell lymphoma：the phase 2 ZUMA-12 trial[J]. Nat
pact of tisagenlecleucel chimeric antigen receptor（CAR）- Med，2022，28（4）：735-742.
T cell therapy product attributes on clinical outcomes in [17] PINNIX C C，GUNTHER J R，DABAJA B S，et al. Brid-
adults with relapsed or refractory diffuse large B-cell lym‐ ging therapy prior to axicabtagene ciloleucel for relapsed/
phoma（r/r DLBCL）[J]. Blood，2019，134：242. refractory large B-cell lymphoma[J]. Blood Adv，2020，4
[ 7 ] SLIM K，NINI E，FORESTIER D，et al. Methodological （13）：2871-2883.
index for non-randomized studies（minors）：development [18] SCHUSTER S J，TAM C S，BORCHMANN P，et al.
and validation of a new instrument[J]. ANZ J Surg，2003， Long-term clinical outcomes of tisagenlecleucel in pa‐
73（9）：712-716. tients with relapsed or refractory aggressive B-cell lym‐
[ 8 ] BALDUZZI S，RÜCKER G，SCHWARZER G. How to phomas（JULIET）：a multicentre，open-label，single-arm，
perform a meta-analysis with R：a practical tutorial[J]. phase 2 study[J]. Lancet Oncol，2021，22（10）：1403-1415.
Evid Based Ment Health，2019，22（4）：153-160. [19] WUDHIKARN K，PALOMBA M L，PENNISI M，et al.
[ 9 ] ABRAMSON J S，PALOMBA M L，GORDON L I，et al. Infection during the first year in patients treated with
Lisocabtagene maraleucel for patients with relapsed or re‐ CD19 CAR T cells for diffuse large B cell lymphoma[J].
fractory large B-cell lymphomas （TRANSCEND NHL Blood Cancer J，2020，10（8）：79.
001）：a multicentre seamless design study[J]. Lancet， [20] WANG L，LI L R，YOUNG K H. New agents and regi‐
2020，396（10254）：839-852. mens for diffuse large B cell lymphoma[J]. J Hematol On‐
[10] BISHOP M R，DICKINSON M，PURTILL D，et al. col，2020，13（1）：175.
Second-line tisagenlecleucel or standard care in aggres‐ [21] STERNER R C，STERNER R M. CAR-T cell therapy：
sive B-cell lymphoma[J]. N Engl J Med，2022，386（7）： current limitations and potential strategies[J]. Blood Can‐
629-639. cer J，2021，11（4）：69.
[11] FARAMAND R，JAIN M，STAEDTKE V，et al. Tumor [22] KOCHENDERFER J N，DUDLEY M E，KASSIM S H，et
microenvironment composition and severe cytokine re‐ al. Chemotherapy-refractory diffuse large B-cell lym‐
lease syndrome（CRS）influence toxicity in patients with phoma and indolent B-cell malignancies can be effec‐
large B-cell lymphoma treated with axicabtagene ciloleu‐ tively treated with autologous T cells expressing an anti-
cel[J]. Clin Cancer Res，2020，26（18）：4823-4831. CD19 chimeric antigen receptor[J]. J Clin Oncol，2015，33
[12] IACOBONI G，VILLACAMPA G，MARTINEZ-CIBRIAN （6）：540-549.
N，et al. Real-world evidence of tisagenlecleucel for the [23] JUNE C H，SADELAIN M. Chimeric antigen receptor
treatment of relapsed or refractory large B-cell lymphoma therapy[J]. N Engl J Med，2018，379（1）：64-73.
[J]. Cancer Med，2021，10（10）：3214-3223. [24] ROBERTS Z J，BETTER M，BOT A，et al. Axicabtagene
[13] LOCKE F L，GHOBADI A，JACOBSON C A，et al. Long- ciloleucel，a first-in-class CAR T cell therapy for aggres‐
term safety and activity of axicabtagene ciloleucel in re‐ sive NHL[J]. Leuk Lymphoma，2018，59（8）：1785-1796.
fractory large B-cell lymphoma（ZUMA-1）：a single-arm， [25] BRUDNO J N，KOCHENDERFER J N. Recent advances
multicentre，phase 1-2 trial[J]. Lancet Oncol，2019，20 in CAR T-cell toxicity：mechanisms，manifestations and
（1）：31-42. management[J]. Blood Rev，2019，34：45-55.
[14] LOCKE F L，MIKLOS D B，JACOBSON C A，et al. Axi‐ [26] WUDHIKARN K，PENNISI M，GARCIA-RECIO M，et
cabtagene ciloleucel as second-line therapy for large B- al. DLBCL patients treated with CD19 CAR T cells expe‐
cell lymphoma[J]. N Engl J Med，2022，386（7）：640-654. rience a high burden of organ toxicities but low nonre‐
[15] NASTOUPIL L J，JAIN M D，FENG L，et al. Standard-of- lapse mortality[J]. Blood Adv，2020，4（13）：3024-3033.
care axicabtagene ciloleucel for relapsed or refractory [27] WANG W X，JIANG J T，WU C P. CAR-NK for tumor
large B-cell lymphoma：results from the US lymphoma immunotherapy：clinical transformation and future pro-
CAR T consortium[J]. J Clin Oncol，2020，38（27）：3119- spects[J]. Cancer Lett，2020，472：175-180.
3128. （收稿日期：2022-05-23 修回日期：2022-09-15）
[16] NEELAPU S S，DICKINSON M，MUNOZ J，et al. Axi‐ （编辑：刘明伟）
cabtagene ciloleucel as first-line therapy in high-risk large

中国药房 2022年第33卷第21期 China Pharmacy 2022 Vol. 33 No. 21 ·2665·